Tristel PLC · LSE:TSTL
Tristel — H1 2024 Earnings Presentation
21 slides from Tristel's earnings presentation, February 2024

Slide 1: Tristel Plc Interim Results Investor Presentation
31 DECEMBER 2023 TRISTEL PLC INTERIM RESULTS INVESTOR PRESENTATION Paul Swinney, CEO Liz Dixon, CFO Heidi Allard, CFC 26-28 February 2024 1

Slide 2: Our Company
Our Company • Global infection prevention • Focus on healthcare • Unique proposition: chlorine dioxide Decontamination of medical Hospital surface disinfection: instruments by hand sporicidal efficacy & sustainability Simple, focussed, global opportunity 2

Slide 3: Multiple Revenue Sources Within The Hospital
Multiple Revenue Sources Within The Hospital Department Medical Device % of Group Area Surface % of Group revenue revenue Obs & gynae Trans-vaginal u/sound probes Mattresses Radiology Trans-rectal u/sound probes 38% IV Poles Hospital wide Skin-surface u/sound probes Trolleys ENT Nasendoscopes 20% Ho

Slide 4: Financial Highlights
Financial Highlights • 20% growth in turnover to a record level of £20.9m (2022: £17.5m) • Overseas sales continue to grow, up 13% to £12.7m (2022: £11.2m) • Reported EBITDA up 21% to £4.7m (2022: £3.9m) • Adjusted* EBITDA up 18% to £5.4m (2022: £4.6m), a margin of 26% (2022: 26%) • Reported profit

Slide 5: Operational Highlights
Operational Highlights • First manufacture and launch of Tristel ULT into the United States ultrasound market • Approval of Tristel ULT by Health Canada post period end • UK & EU Medical Device Regulation reviews of Cache Tank and Capsule successfully concluded and positive recommendation for UKCA a

Slide 6: 10 Year H-O-H Sales Growth Record
10 Year H-O-H Sales Growth Record 40,000 35,000 30,000 Sources of £3.4m 25,000 period on period growth: Revenue £'000 20,000 H2 • £1.5m volume H1 15,000 • £1.9m pricing 10,000 5,000 - 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Y-o-y 14% 12% 19% 10% 18% 21% -2% 0% 16% 20% Growth rate 6

Slide 7: Sales Growth by Geography
Sales Growth by Geography Period on £m Geography 2023-24 2022-23 period % change change Direct Australasia 2.3 2.2 0.1 5% Direct China & Hong Kong 1.0 1.0 - - Direct Malaysia & Singapore 0.4 0.4 - - Direct Western Europe 3.0 2.7 0.3 11% Direct Central Europe 3.3 2.9 0.4 14% Direct Southern Europe 0.

Slide 8: Sales Growth by Portfolio and Channel
Sales Growth by Portfolio and Channel Period on £m Channel 2023-24 2022-23 Period % change change Tristel Hospital UK direct 6.6 4.6 2.0 43% Medical Device EMEA direct 6.6 5.8 0.8 14% Decontamination APAC direct 3.3 3.1 0.2 6% Worldwide distributors 1.8 1.2 0.6 50% 18.3 14.7 3.6 25% Cache Hospital U

Slide 9: North America – Ultrasound Opportunity
North America – Ultrasound Opportunity • Tristel ULT: high-level disinfectant for endo-cavity probes & skin surface transducers approved by both FDA and Health Canada • 50m ultrasound scans in North America require high-level disinfection annually • Translates to a US$100m p.a. Tristel/Parker revenu

Slide 10: North America – Ultrasound Progress
North America – Ultrasound Progress 2018-2023: Commercial partnership with Parker Laboratories developed for the manufacture and distribution of Tristel ULT in the USA and Canada June 2023: USA FDA approves Tristel ULT June 2023: Tristel ULT is launched at the American Infection Prevention Congress

Slide 11: North America - Ophthalmology Opportunity
North America - Ophthalmology Opportunity • Devices touching cornea require high-level disinfection (Spaulding Classification) • Universally, they are only low-level disinfected • Eye-related infection risks well known: conjunctivitis affects ~ 6m people annually in United States • Devices are known

Slide 12: North America – Ophthalmology Progress
North America – Ophthalmology Progress Canada: Canada Health approved Tristel OPH in June 2021 Innova Medical Ophthalmics, Toronto, appointed as national distributor for Canada in 2022 Alberta Health Services becomes first user 24 repeat users across Canada, 12% market penetration USA: 510(K) submis

Slide 13: Product Development
Product Development 3T platform: AI: Colour change technology: App-based Train, Trace and Capabilities incorporated into Visual indicators to ensure key Test tool to record all steps of the app for objective steps in the decontamination the decontamination process. verification that the key steps pr

Slide 14: FY23 - FY25 Financial Targets
FY23 - FY25 Financial Targets • Sales growth in the range of 10% to 15% per annum as an annual average over three years • EBITDA margin (excluding share-based payment charge) of at least 25% Due to CEO succession new targets deferred until October 2024 14

Slide 15: ESG Highlights
ESG Highlights • ESG strategy published • Carbon Zero target of 2030 and route to success defined • Carbon profiling of key products underway with packaging adjustments and reductions planned • Partnership with ESG consultants to ensure best practice adhered to • Recruitment into specialist sustaina

Slide 16: Summary & Outlook
Summary & Outlook • A record set of results on all levels • Significant growth opportunity in both portfolios • Profitable, cash generative, debt free, progressive dividend • Exciting future ahead Simple, focussed, global opportunity 16

Slide 17: Any questions?
Tsidl Any questions? Tristel

Slide 18: Appendix – Income Statement
Period ended Period ended APPENDIX – INCOME STATEMENT 31.12.23 31.12.22 £’000 £’000 Turnover 20,943 17,463 Cost of sales (3,401) (3,322) Gross profit 17,542 14,141 Gross margin % 84% 81% Distribution expenses (274) (198) Administrative and distribution expenses less other operating income (11,833) (

Slide 19: Appendix – Balance Sheet
APPENDIX – BALANCE SHEET 31.12.23 31.12.22 Non-current assets £’000 £’000 Goodwill 5,152 5,325 Intangible assets 4,579 3,828 Property, plant and equipment 8,369 7,968 Deferred tax 626 1,058 18,726 18,179 Current assets Inventories 4,450 4,668 Trade and other receivables 6,226 6,394 Income tax receiv

Slide 20: Appendix – Balance Sheet Continued
APPENDIX – BALANCE SHEET …Continued 31.12.23 31.12.22 Capital and reserves £’000 £’000 Share capital 475 473 Share premium account 14,530 14,010 Merger reserve 2,205 2,205 Foreign exchange reserve (215) 123 Retained earnings 14,127 12,095 Non-controlling interests 7 7 Total equity 31,129 28,913 Curr

Slide 21: Appendix – Cash Flow Statement
APPENDIX – CASH FLOW STATEMENT Period ended Period ended 31.12.23 31.12.22 £’000 £’000 Profit before tax 3,437 2,388 Add back non-cash items 1,997 2,121 Working capital movements (222) (316) Interest received 125 - Purchase of tangible fixed assets (218) (128) Purchase of intangible assets (300) (29
Source: Internet Archive copy of investors.tristel.com
More decks from Tristel PLC
ShareSoc Leeds (April 2026)26 slides · April 2026
FY2025 Earnings Presentation49 slides · October 2025
Investor Presentation (June 2025)15 slides · June 2025
Q2 2025 Earnings Presentation31 slides · Feb 24, 2025
Investor Presentation (October 2024)28 slides · October 2024
Investor Presentation (October 2023)10 slides · Oct 19, 2023